Revance Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Revance Therapeutics

29/02/2024 24:04

* Revance Therapeutics Inc  RVNC.OQ  reported a quarterly
adjusted
loss of 62 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -95 cents.  The mean expectation of
twelve analysts for the quarter was for a loss of 72 cents per
share. Wall Street expected results to range from $-1.01 to -45
cents per share.
    * Revenue rose 39.8% to $69.80 million from a year ago;
analysts
expected $62.12 million. 
    * Revance Therapeutics Inc's reported EPS for the quarter
was a
loss of 62 cents​.
    * The company reported a quarterly loss of $55.7 million.
    * Revance Therapeutics Inc shares had fallen by 35.2% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 10.2%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Revance
Therapeutics Inc is $12.00 
This summary was machine generated from LSEG data February 29 at
12:03 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.72          -0.62          Beat
 Sep. 30 2023      -0.85          -1.63          Missed
 Jun. 30 2023      -0.78          -0.80          Missed
 Mar. 31 2023      -0.70          -0.74          Missed